Determination of Angptl4 mRNA as a Diagnostic Marker of Primary and Metastatic Clear Cell Renal-Cell Carcinoma

Background We have previously shown that angiopoietin-like 4 (angptl4) mRNA, a hypoxia-inducible gene, is highly expressed in clear cell renal-cell carcinoma (ccRCC), the most common subtype of RCC for which no specific marker is available. We here investigated whether angptl4 mRNA 1) could be a useful diagnostic and/or prognostic marker of ccRCC in a large and comprehensive retrospective series, 2) induction is dependent on the VHL status of tumors. Methodology/Principal Findings Using in situ hybridization, we report that angptl4 mRNA is expressed in 100% of both sporadic (n = 102) and inherited (n = 6) primary ccRCCs, without any statistical association with nuclear grade (p = 0.39), tumor size (p = 0.09), stage grouping (p = 0.17), progression-free survival (p = 0.94), and overall survival (p = 0.80). Angptl4 mRNA was also expressed in 26 (87%) of 30 secondary ccRCCs but neither in any other secondary RCCs (n = 7). In contrast, angptl4 mRNA was neither expressed in 94% non-ccRCC renal tumors (papillary RCCs (n = 46), chromophobe RCCs (n = 28), and oncocytomas (n = 9)), nor in non-renal clear cell carcinomas (n = 39). Angptl4 expression was also examined in tumors associated (n = 23) or not associated (n = 66) with VHL disease. 40 (98%) hemangioblastomas expressed angptl4 whereas all pheochromocytomas (n = 23) and pancreatic tumors (n = 25) were angptl4-negative, whatever their VHL status. Conclusions/Significance Angptl4 mRNA expression was highly associated with ccRCC (p = 1.5 10−49, Chi square test) allowing to define its expression as a diagnosis marker for primary ccRCC. Moreover, angptl4 mRNA allows to discriminate the renal origin of metastases of clear-cell carcinomas arising from various organs. Finally, inactivation of VHL gene is neither necessary nor sufficient for angptl4 mRNA induction.

[1]  Todd H. Stokes,et al.  Diagnostic biomarkers for renal cell carcinoma: selection using novel bioinformatics systems for microarray data analysis. , 2009, Human pathology.

[2]  E. van Marck,et al.  An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. , 2009, The Lancet. Oncology.

[3]  M. Wirth,et al.  Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease‐free interval and the number of metastases per patient , 2009, International journal of cancer.

[4]  A. Lopez‐Beltran,et al.  2009 update on the classification of renal epithelial tumors in adults , 2009, International journal of urology : official journal of the Japanese Urological Association.

[5]  A. Xu,et al.  A Highly Conserved Motif within the NH2-terminal Coiled-coil Domain of Angiopoietin-like Protein 4 Confers Its Inhibitory Effects on Lipoprotein Lipase by Disrupting the Enzyme Dimerization* , 2009, Journal of Biological Chemistry.

[6]  S. Richard,et al.  Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease: Characterization by VHL/HIF Pathway Proteins Expression , 2009, The American journal of surgical pathology.

[7]  Zhiyuan Hu,et al.  A compact VEGF signature associated with distant metastases and poor outcomes , 2009, BMC medicine.

[8]  S. Ricard-Blum,et al.  Interaction of the coiled‐coil domain with glycosaminoglycans protects angiopoietin‐like 4 from proteolysis and regulates its antiangiogenic activity , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  B. Williams,et al.  Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. , 2009, The Journal of urology.

[10]  M. Amin,et al.  Diagnostic Implications of Transcription Factor Pax 2 Protein and Transmembrane Enzyme Complex Carbonic Anhydrase IX Immunoreactivity in Adult Renal Epithelial Neoplasms , 2009, The American journal of surgical pathology.

[11]  D. Pascual,et al.  Epidemiology of Kidney Cancer , 2008, Advances in urology.

[12]  W. Kaelin.  The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer , 2008, Nature Reviews Cancer.

[13]  J. McKenney,et al.  The Utility of PAX-2 in Distinguishing Metastatic Clear Cell Renal Cell Carcinoma From its Morphologic Mimics: An Immunohistochemical Study With Comparison to Renal Cell Carcinoma Marker , 2008, American Journal of Surgical Pathology.

[14]  F. Waldman,et al.  Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors , 2008, Clinical Cancer Research.

[15]  J. Vignaud,et al.  Immunohistochemical Markers to Distinguish Between Hemangioblastoma and Metastatic Clear-cell Renal Cell Carcinoma in the Brain: Utility of Aquaporin1 Combined With Cytokeratin AE1/AE3 Immunostaining , 2008, The American journal of surgical pathology.

[16]  S. McKenna,et al.  Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. , 2008, Biochemical Society transactions.

[17]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[18]  B Cochand-Priollet,et al.  Profiling and classification tree applied to renal epithelial tumours , 2007, Histopathology.

[19]  G. Martignoni,et al.  TNM staging system for renal-cell carcinoma: current status and future perspectives. , 2007, The Lancet. Oncology.

[20]  Pierre Corvol,et al.  Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness , 2006, Proceedings of the National Academy of Sciences.

[21]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  Kentaro Takahashi,et al.  Von Hippel-Lindau Disease , 2024 .

[23]  J. Ortiz‐Rey,et al.  [Expression of CD10 and renal cell carcinoma marker in clear cell renal cell carcinoma: analysis on tissue arrays]. , 2006, Actas urologicas espanolas.

[24]  F. McGovern,et al.  Renal-cell carcinoma. , 2005, The New England journal of medicine.

[25]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[26]  M. Amin,et al.  An immunohistochemical approach to the differential diagnosis of renal tumors. , 2005, Seminars in diagnostic pathology.

[27]  C. Pan,et al.  The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases , 2004, Histopathology.

[28]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[29]  Pierre Corvol,et al.  Angiopoietin-like 4 is a proangiogenic factor produced during ischemia and in conventional renal cell carcinoma. , 2003, The American journal of pathology.

[30]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[31]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[33]  J. A. Ortiz-Rey,et al.  Expresión de CD10 y del marcador de carcinoma renal en el carcinoma renal de células claras: análisis en matrices tisulares. , 2006 .

[34]  M. Karno,et al.  Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.